Prediction of a clinically effective dose of THY1773, a novel V 1B receptor antagonist, based on preclinical data-Reference-Cited by-同舟云学术

Prediction of a clinically effective dose of THY1773, a novel V 1B receptor antagonist, based on preclinical data

Published:2021-04-03 Issue:5 Volume:42 Page:204-217
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm Drug Dispos

Author:

Inatani Shoko¹^ORCID,Mizuno‐Yasuhira Akiko¹,Kamiya Makoto²³,Nishino Izumi²,Sabia Helene D.⁴,Endo Hiromi¹

Affiliation:

1. Drug Metabolism and Pharmacokinetics Drug Safety and Pharmacokinetics Laboratories Research Headquarters Taisho Pharmaceutical Co., Ltd. Saitama Japan

2. Development Headquarters Taisho Pharmaceutical Co., Ltd. Tokyo Japan

3. Drug Development Taisho Pharmaceutical R&D Inc. NJ USA

4. Clinical Operations Taisho Pharmaceutical R&D Inc. NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bdd.2273

Reference41 articles.

1. Fluid Shifts and Other Factors Affecting Plasma Protein Binding of Prednisolone by Equilibrium Dialysis

2. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction

3. In Vitro–In Vivo Inaccuracy: The CYP3A4 Anomaly

4. Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

5. Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention;Psychiatry and Clinical Neurosciences;2024-06-25

2. Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia;Pharmacology Research & Perspectives;2024-03-15

3. Vasopressin as Possible Treatment Option in Autism Spectrum Disorder;Biomedicines;2023-09-22

4. Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders;Neuropsychiatric Disease and Treatment;2023-04

5. Epigenetic Modulation of Vasopressin Expression in Health and Disease;International Journal of Molecular Sciences;2021-08-30